RBC Capital analyst Gerard Cassidy lowered the firm’s price target on Goldman Sachs (GS) to $560 from $610 and keeps a Sector Perform rating on ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $217.00. The ...

Goldman Sachs analyst Alexander Blostein expects macro and policy uncertainty, volatile equity markets, and declining short-term interest rates to weigh on EPS forecasts for Capital Markets stocks.

On Monday, Bank of America joined the likes of Oppenheimer, JPMorgan, Goldman Sachs, RBC Capital Markets, Barclays, Evercore ISI, and Yardeni Research in lowering its year-end S&P 500 forecast.

J.P.Morgan ratcheted up its odds for a U.S. and global recession to 60%, as brokerages scrambled to revise their forecast ...

Teams at Goldman Sachs, Bank of America, Evercore ISI, RBC Capital Markets, and JPMorgan each see the S&P 500 now ending 2025 ...

Now that earnings season is underway again, investors get a chance to see what's happening behind the scenes of the financial sector, including some of the main players of the United States ...

Goldman Sachs reported a 15% rise in first-quarter ... upend global trade norms could hit a slew of firms reliant on capital markets activity. Revenue at Goldman's asset and wealth management ...

Goldman Sachs sees macro uncertainty, rate cuts, and weak equity markets pressuring Capital Markets EPS forecasts. Alternative Managers face EPS risks, while Exchanges remain resilient ...

Goldman Sachs analyst Alexander Blostein expects macro and policy uncertainty, volatile equity markets, and declining short-term interest rates to weigh on EPS forecasts for Capital Markets stocks.